Axogen, Inc. (AXGN)Healthcare | Medical Devices | Alachua, United States | NasdaqCM
39.49 USD
-1.09
(-2.686%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 39.49 |
Hot Take ↕ | July 11, 2026, 6:11 a.m. EDT
The immediate outlook is driven by a sharp technical rebound and aggressive speculative positioning. After a brutal multi-year grind from 2018 to 2024, the stock has staged a massive recovery, nearly tripling in value over the last few years to trade near its 52-week highs. This resurgence has attracted heavy options speculation, with traders stacking call open interest at the $50 strike, betting on a continuation of this trend. However, the fundamental reality remains starkly different from the price action: the company is currently unprofitable with negative operating margins and a forward P/E that implies significant future earnings growth. While the balance sheet is surprisingly healthy with minimal debt and strong cash flow, the lack of a dividend and the persistent losses suggest the current rally is priced on a turnaround thesis rather than current execution. The statistical forecast model offers only a weak lean upward, confirming that while the momentum is real, the predictive signal is noisy. For investors, this is a high-risk, high-reward momentum play dependent on the company executing its turnaround, rather than a safe value investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.096172 |
| MSTL_74 | 0.150689 |
| MSTL_126 | 0.157687 |
| MSTL_74_126 | 0.166352 |
| MSTL | 0.181960 |
| AutoTheta | 0.188391 |
| AutoETS | 0.191428 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.51 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.989 |
| Excess Kurtosis | 0.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2010-01-26 |
| Last Dividend Date | 2010-01-26 |
| Debt to Equity Ratio | 8.432 |
| Revenue per Share | 4.997 |
| Market Cap | 2,099,992,320 |
| Forward P/E | 54.22 |
| Beta | 1.09 |
| Profit Margins | -13.21% |
| Website | https://www.axogeninc.com |
As of July 11, 2026, 6:11 a.m. EDT: Speculators are heavily skewed toward bullish exposure, with open interest concentrated significantly in out-of-the-money calls (50 strike) compared to puts. The call side shows a distinct 'top OI' at the 50 strike for both July and August expirations, suggesting a speculative bet on a move to $50+. Put activity is sparse and mostly clustered deep in-the-money or at the money, indicating limited hedging against a crash. Implied volatility is elevated on the call side relative to the put side, reflecting asymmetric fear/greed where the upside potential is priced higher than the downside protection.
| Date | Dividend | Yield % |
|---|---|---|
| 2010-01-27 | 1.000000 | 22.222222 |
| 2005-02-23 | 0.060000 | 2.608696 |
| 1992-07-10 | 0.041723 | 0.497293 |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.37604 |
| Address1 | 13,631 Progress Boulevard |
| Address2 | Suite 400 |
| All Time High | 56.85 |
| All Time Low | 0.2 |
| Ask | 50.11 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,731,690 |
| Average Daily Volume3 Month | 1,260,093 |
| Average Volume | 1,260,093 |
| Average Volume10Days | 1,731,690 |
| Beta | 1.089 |
| Bid | 29.58 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 4.606 |
| City | Alachua |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 39.49 |
| Current Ratio | 7.101 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 41.52 |
| Day Low | 39.09 |
| Debt To Equity | 8.432 |
| Display Name | Axogen |
| Dividend Date | 1,265,932,800 |
| Earnings Call Timestamp End | 1,777,377,600 |
| Earnings Call Timestamp Start | 1,777,377,600 |
| Earnings Timestamp | 1,777,379,400 |
| Earnings Timestamp End | 1,777,379,400 |
| Earnings Timestamp Start | 1,777,379,400 |
| Ebitda | -2,135,000 |
| Ebitda Margins | -0.00897 |
| Enterprise To Ebitda | -945.683 |
| Enterprise To Revenue | 8.48 |
| Enterprise Value | 2,019,033,216 |
| Eps Current Year | 0.48857 |
| Eps Forward | 0.72833 |
| Eps Trailing Twelve Months | -0.62 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,264,550,400 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 386 462 6801 |
| Fifty Day Average | 42.595 |
| Fifty Day Average Change | -3.1049995 |
| Fifty Day Average Change Percent | -0.07289587 |
| Fifty Two Week Change Percent | 237.604 |
| Fifty Two Week High | 46.95 |
| Fifty Two Week High Change | -7.459999 |
| Fifty Two Week High Change Percent | -0.15889242 |
| Fifty Two Week Low | 11.25 |
| Fifty Two Week Low Change | 28.240002 |
| Fifty Two Week Low Change Percent | 2.5102224 |
| Fifty Two Week Range | 11.25 - 46.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 535,213,800,000 |
| Float Shares | 52,021,738 |
| Forward Eps | 0.72833 |
| Forward P E | 54.21993 |
| Free Cashflow | 18,294,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 622 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.75013 |
| Gross Profits | 178,608,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02187 |
| Held Percent Institutions | 0.93784 |
| Implied Shares Outstanding | 53,177,824 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,264,550,400 |
| Last Dividend Value | 1.0 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 773,884,800 |
| Last Split Factor | 105:100 |
| Long Business Summary | Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida. |
| Long Name | Axogen, Inc. |
| Market | us_market |
| Market Cap | 2,099,992,320 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_20946777 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -31,453,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,157,424,319 |
| Number Of Analyst Opinions | 9 |
| Open | 40.06 |
| Operating Cashflow | 15,556,000 |
| Operating Margins | -0.046079997 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 99.04 |
| Phone | 386 462 6800 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 39.49 |
| Post Market Time | 1,783,981,120 |
| Previous Close | 40.58 |
| Price Eps Current Year | 80.82772 |
| Price Hint | 2 |
| Price To Book | 8.5736 |
| Price To Sales Trailing12 Months | 8.819607 |
| Profit Margins | -0.1321 |
| Quick Ratio | 4.994 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | -1.09 |
| Regular Market Change Percent | -2.68605 |
| Regular Market Day High | 41.52 |
| Regular Market Day Low | 39.09 |
| Regular Market Day Range | 39.09 - 41.52 |
| Regular Market Open | 40.06 |
| Regular Market Previous Close | 40.58 |
| Regular Market Price | 39.49 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,261,532 |
| Return On Assets | -0.02322 |
| Return On Equity | -0.17964001 |
| Revenue Growth | 0.266 |
| Revenue Per Share | 4.997 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 53,177,824 |
| Shares Percent Shares Out | 0.0872 |
| Shares Short | 4,634,995 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,369,844 |
| Short Name | AxoGen, Inc. |
| Short Percent Of Float | 0.1009 |
| Short Ratio | 3.24 |
| Source Interval | 15 |
| State | FL |
| Symbol | AXGN |
| Target High Price | 55.0 |
| Target Low Price | 48.0 |
| Target Mean Price | 50.77778 |
| Target Median Price | 50.0 |
| Total Cash | 101,601,000 |
| Total Cash Per Share | 1.911 |
| Total Debt | 20,642,000 |
| Total Revenue | 238,104,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 32.34145 |
| Two Hundred Day Average Change | 7.148552 |
| Two Hundred Day Average Change Percent | 0.22103375 |
| Type Disp | Equity |
| Volume | 1,261,532 |
| Website | https://www.axogeninc.com |
| Zip | 32,615 |